Assessing chloroquine toxicity in RA patients using retinal nerve fibre layer thickness, multifocal electroretinography and visual field test

British Journal of Ophthalmology

Volumn 94, Issue 12, 2010, Pages 1632-1636

  Xiaoyun, M A ^a   Dongyi, H E ^a   Linping, H E ^a  

^a Guanghua Rheumatoid Arthritis Specialized Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE;

ADULT; AGED; ARTICLE; CENTRAL SCOTOMA; CONTROLLED STUDY; ELECTRORETINOGRAPHY; EYE FUNDUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIFOCAL ELECTRORETINOGRAPHY; POLARIMETRY; PRIORITY JOURNAL; RETINA NERVE CELL; RETINA NERVE FIBER LAYER THICKNESS; RHEUMATOID ARTHRITIS; SCOTOMA; VISUAL ACUITY; VISUAL FIELD;

ADULT; AGED; ANTIRHEUMATIC AGENTS; CHLOROQUINE; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; ELECTRORETINOGRAPHY; FEMALE; HUMANS; MIDDLE AGED; NERVE FIBERS; PROSPECTIVE STUDIES; RETINAL DISEASES; VISUAL FIELD TESTS;

EID: 78649899393     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.171082     Document Type: Article

References (25)

1. Uhlemann AC, Krishna S. Antimalarial multi-drug resistance in Asia: mechanisms and assessment. Curr Top Microbiol Immunol 2005;295:39-53.
2. Neubauer AS, Samari-Kermani K, Schaller U, et al. Detecting chloroquine retinopathy: electro-oculogram versus colour vision. Br J Ophthalmol 2003;87:902-8.
3. Savarino A, Lucia MB, Giordano F, Cauda R. Risks and benefits of chloroquine use in anticancer strategies. Lancet Oncol 2006;7:792-3.
4. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med 1988;85:23-9.
5. Rosenthal AR, Kolb H, Bergsma D, et al. Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 1978;17:1158-75.
6. Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol 2002;133:649-56.
7. Shinjo SK, Maia OO Jr, Tizziani VA, et al. Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration? Clin Rheumatol 2007;26:1248-53.
8. Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/ hydroxychloroquine. Invest Ophthalmol Vis Sci 2006;47:3531-8.
9. Lai TY, Chan WM, Li H, et al. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol 2005;140:794-807.
10. Kellner S, Weinitz S, Kellner U. Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and near-infrared autofluorescence. Br J Ophthalmol 2009;93:1444-7.
11. Kellner U, Kellner S, Weinitz S. Chloroquine retinopathy: lipofuscin-and melanin-related fundus autofluorescence, optical coherence tomography and multifocal electroretinography. Doc Ophthalmol 2008;116:119-27.
12. Duncker G, Bredehorn T. Chloroquine-induced lipidosis in the rat retina: functional and morphological changes after with-drawal of the drug. Graefes Arch Clin Exp Ophthalmol 1996;234:378-81.
13. Yoshida T, Fukatsu R, Tsuzuki K, et al. Amyloid precursor protein, A beta and amyloid-associated proteins involved in chloroquine retinopathy in rats - immunopathological studies. Brain Res 1997;764:283-8.
14. Nebbioso M, Grenga R, Karavitis P. Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy. J Ocul Pharmacol Ther 2009;25:1-10.
15. Bonanomi MTBC, Dantas NC, Medeiros FA. Retinal nerve fibre layer thickness measurements in patients using chloroquine. Clin Experiment Ophthalmol 2006;34:130-6.
16. Bagga H, Greenfield DS, Knighton RW. Scanning laser polarimetry with variable corneal compensation: identification and correction for corneal birefringence in eyes with macular pathology. Invest Vis Sci Ophthalmol 2003;44:1969-76.
17. Hood DC, Bach M, Brigell M, et al. ISCEV guidelines for clinical multifocal electroretinography (2007 edition). Doc Ophthalmol 2008;116:1-11.
18. Sutter EE, Tran D. The field topography of ERG components in man. The photopic luminance response. Vision Res 1992;32:433-66.
19. Moschos MN, Moschos MM, Apostolopoulos M, et al. Assessing hydroxychloroquine toxicity by the multifocal ERG. Doc Ophthalmol 2004;108:47-53.
20. Lai TYY, Ngai JWS, Chan WM, et al. Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy. Doc Ophthalmol 2006;112:177-87.
21. Elder M, Rahman AMA, Mclay J. Early paracentral visual field loss in patients taking hydroxychloroquine. Arch Ophthalmol 2006;124:1729-33.
22. Hanna B, Holdeman NR, Tang RA, et al. Retinal toxicity secondary to Plaquenil therapy. Optometry 2008;79:90-4.
23. Kellner U, Kraus H, Foerster MH. Multifocal ERG in chloroquine retinopathy: regional variance of retinal dysfunction. Graefes Arch Clin Exp Ophthalmol 2000;238:94-7.
24. Maturi RK, Folk JC, Nichols B, et al. Hydroxychloroquine retinopathy. Arch Ophthalmol 1999;117:1262-3.
25. Marmor MF. The dilemma of hydroxychloroquine screening: new information from the multifocal ERG. Am J Ophthalmol 2005;140:894-5.